Table 5.

Results and prognostic factors of MSGTs in last decade

	No. of Pts	Radiation Technique	Median Follow-up	Locoregional Control (LRC)	Distant Control (DC)	Survival	Prognostic Factors
Tam (2013)	200	IMRT, 3D-CRT, or conventional	50 months	2y LC 91% 5y LC 88% 2y RC 96% 5y RC 94%	2y DMFS 84% 5y DMFS 73%	5y 76.6%	T classification, N classification associated with DC; N classification associated with survival
Jensen (2015)	53	IMRT and Carbon Ion Boost	42 months	2y LC 84.3% 3y LC 81.9%	3y PFS 57.9%	3y 78.4%	-
Jegadeesh (2015)	112	-	55.1 months	5y LRC stages I/II 94.6 stages III/IV 60.4%	5y DC stages I/II 93.0% stages III/IV 56.9%	5y 76.0%	CNI, age, tumor size associated with LRC; site, FNP, high grade, T classification, tumor size associated with DC
Hosni (2016)	304	3D-CRT or IMRT	82 months	5y LC 96% 5y RC 95%	5y DC 80%	5y 78%	Stage III–IVB, LVI, surgical margin, high risk pathology associated with DC; Stage III–IVB, LVI associated with survival
Haderlein (2019)	65	3D-CRT or IMRT	45 months	3y LC 93% 3y LRC 90.3%	3y DC 64%	3y 74.9%	Macroscopic resection margin (R2) associated with LC

Intensity modulated radiation therapy (IMRT); 3-dimensional conformal radiation therapy (3D-CRT); Local control (LC); Regional control (RC); Distant metastasis-free survival (DMFS); Progression-free survival (PFS); Clinical nerve involvement (CNI), facial nerve paralysis (FNP).